RenovoRx, Inc.

NASDAQ: RNXT · Healthcare · Biotechnology

PublicHQ Mountain View, CA · Santa ClaraCIK 0001574094Reports USD

#865 of 1,422 Healthcare companies by revenuetop-decile growth

EA Score

32D

FH 38DQ 23GM —SS 37

v0.1 · 55/100 weight · provisional

↑ revenue growth (YoY), balance-sheet leverage · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

$1.5M

Rev growth YoY (TTM)

+520.4%

Net income (FY)

-$11.2M

Employees

as of 2026-08-20

Market cap

$59.2M

as of 2026-08-20

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$1.1M$1.1M2025

Net income-$11.2M-$11.2M2025

Operating income-$12.5M-$12.5M2025

Total assets$8.1M$8.1M2025

Liabilities$2.7M$2.7M2025

Equity$5.4M$5.4M2025

Revenue by segment

Filed disclosures · FY2025

By product

Other Operating100%

By geography

Not disclosed.

The read

What is RenovoRx, Inc.’s revenue?

RenovoRx, Inc. booked $1.1M in FY2025 revenue, growing 2512% year over year — faster than 97% of Healthcare companies we track, at a -994.5% net margin.

Peers · Healthcare

Peoplesway.com Inc.——Ampio Pharmaceuticals, Inc.——PetVivo Holdings, Inc.38D Bespoke Extracts, Inc.——Kaleido Biosciences, Inc.——White River Energy Corp.——

Neighbors

Santa Clara →

NVIDIA Corporation$215.9B90A Apple Inc.$416.2B84B+Alphabet Inc.$402.8B81B+Broadcom Inc.$63.9B76B+Advanced Micro Devices, Inc.$34.6B78B+Cisco Systems, Inc.$56.7B85A

Key facts

CEOShaun R. Bagai

SectorHealthcare

IndustryBiotechnology

HeadquartersMountain View, CA

ExchangeNASDAQ: RNXT

Employees17

IPO date2021-08-26

Latest filings

8-K2026-07-02 8-K2026-06-30 10-Q2026-05-14 8-K2026-05-14 DEF 14A2026-04-30 10-K2026-03-30 8-K2026-03-30 8-K2026-03-27

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.